JPRN-UMIN000027270
Recruiting
未知
A study on Prevention of Hypertensive Disorders of Pregnancy who have a history of severe hypertensive disorders of pregnancy -Pre-test for multi center trial
Mie university hospital, Department of Obstetrics and Gynecology0 sites20 target enrollmentMay 15, 2017
ConditionsHypertensive Disorders of Pregnancy
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Hypertensive Disorders of Pregnancy
- Sponsor
- Mie university hospital, Department of Obstetrics and Gynecology
- Enrollment
- 20
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\) 20 years of age or older
- •2\) History of severe Hypertensive disorders of Pregnancy that required delivery prior to 34 weeks' gestation.
- •3\) Gestational age between 12 \+ 0 and 16 \+ 6 weeks (The expected date of confinement is determined using the criteria of the guidelines for obstetrical practice in Japan 2014\.)
- •4\) Singleton pregnancy
- •5\) For the test participation, it has consent is obtained in writing from the patient.
Exclusion Criteria
- •1\)A history of allergy to tadalafil
- •2\)Concurrent medications that interact adversely with tadalafil
- •3\)Relative contraindication of tadalafil treatment due to renal disease.
- •4\)Relative contraindication of tadalafil treatment due to liver disease.
- •5\)Relative contraindication of tadalafil treatment due to uncontrolled arrhythmia, hypertension (BP \>170/110 mmHg), and hypotension (BP \<80/40 mmHg).
- •6\)Fetus with suspected chromosomal disorder and/or multiple congenital anomalies.
- •7\)Relative contraindication of tadalafil treatment due to retinitis pigmentosa, coagulation defect, active gastric and/or intestinal ulcer, and venous obstructive disease.
- •8\)Attending physician decides to entry inappropriate.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
Prevention for Recurrence Of The preEClampsia with TAdalafilJPRN-jRCTs041180121Tanaka Hiroaki20
Not yet recruiting
Phase 1
aotai Fang for prevention and treatment of hypertensive cerebral small vessel disease: randomized, double-blind, placebo-controlled, multi-center clinical trial protocolITMCTR1900002466Hu'nan University of Chinese Medicine
Active, not recruiting
Not Applicable
Stroke Prevention by Antihypertensive Drugs (SPREAD) TrialHypertensionCardiovascular - HypertensionStroke -ACTRN12607000109404Cardiovascular Institute, Chinese Academy of Medical Sciences6,000
Active, not recruiting
Not Applicable
Prevención de la progresión de la hipertensión portal en la cirrosis compensada mediante el uso de vasodilatadores hepáticos selectivos. Estudio multicéntrico, aleatorizado y doble-ciego - SIMPROEl objetivo de estudio es valorar el efecto de las estatinas, en su efecto vasodilatador selectivo hepático, en la prevención de la progresión de la hipertensión portal ( con un gradiente de presión entre 6 y 10 mmHg) en pacientes con cirrosis hepática compensada.MedDRA version: 12.1Level: HLTClassification code 10036201Term: Portal hypertensionsEUCTR2010-021593-11-ESINSTITUT DE RESERCA.HSCSP
Completed
Not Applicable
Hypertension and coronary prevention research projectHypertensionCirculatory SystemEssential (primary) hypertensionISRCTN81113179Department of Health (UK)700